Subscribe
shutterstock_1174421515_eyesonmilan
eyesonmilan / Shutterstock.com
22 August 2019Americas

Gilead challenges US govt patents on HIV drug Truvada

Gilead Sciences, the maker of HIV drug Truvada (emtricitabine/tenofovir), has asked the US Patent and Trademark Office (USPTO) to review patents granted to the government covering preventative use of the drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.

More on this story

Americas
Gilead accused of illegally paying to delay HIV drug competition
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Americas
Gilead fails to have US government patents invalidated
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
US govt PrEP patents are invalid, Gilead tells court
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud
US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug